Arix Bioscience: Multiple inflection points in 2020 (Interview)

Arix Bioscience plc (LON:ARIX) is the topic of conversation when Dr Dorothea Hill, Analyst at Hardman & Co joins DirectorsTalk. Having recently initiated on Arix Bioscience Dorothea explains the key takeaways retail investors should be aware of, how a generalist investor should assess the technology, how to assess Arix’s Net Asset Value, expectations for full year results and what to look for going forward.

Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

They collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, they are able to bring this exciting growth phase of their industry to a broader range of investors.

You might also enjoy reading  Tissue Regenix significantly undervalued against peers (VIDEO)
Find more news, interviews, share price & company profile here for:
Hardman & Co

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Hardman & Co
Arix Bioscience: Multiple inflection points in 2020 (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions